PROSTOX Resources
Physician Tech Note
Clinical information and evidence about PROSTOX for physicians.
Flyer for Patients
Handout that explains PROSTOX and how results guide treatment.
Biling Overview Printout
Printable insurance and billing information to give patients.
Insurance and Billing Policy
Key billing and insurance details for physicians ordering PROSTOX tests.
Financial Assistance Program
Explains how eligible patients can reduce their out-of-pocket costs.
PROSTOX
References:
- Weidhaas JB, Marco N, Steinberg ML, et al. Early findings from the GARUDA trial: The impact of a genetic signature of late radiation toxicity on prostate cancer treatment decision making. J Clin Oncol. 2023;41(16_suppl):5089-5089. doi:https://doi.org/10.1200/jco.2023.41.16_suppl.5089.
- Kishan AU, Marco N, Schulz-Jaavall MB, et al. Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Radiother Oncol. 2022;167:226-232. doi:10.1016/j.radonc.2021.12.040.
- Kishan AU, Marco N, Ma TM, et al. Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial. Clin Transl Radiat Oncol. 2023;39doi:10.1016/j.ctro.2023.100594.
- Kishan AU, McGreevy K, Valle L, et.al. Validation and derivation of microRNA-based germline signatures predicting radiation toxicity in prostate cancer. Clin Cancer Res. 2025 Jun 13;31(12):2530-2538. doi: 10.1158/1078-0432.CCR-24-3951.
- Kishan AU, McGreevy K, Telesca D, Weidhaas JB. Treatment choices and toxicity outcomes in patients with a high-risk PROSTOX score. Int J Radiat Oncol Biol Phys. 2025;123(1):e615. doi:10.1016/j.ijrobp.2025.06.2894.